These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37256341)

  • 21. A multinational study of thromboprophylaxis practice in critically ill children.
    Faustino EV; Hanson S; Spinella PC; Tucci M; O'Brien SH; Nunez AR; Yung M; Truemper E; Qin L; Li S; Marohn K; Randolph AG;
    Crit Care Med; 2014 May; 42(5):1232-40. PubMed ID: 24351371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained low-efficiency dialysis with regional citrate anticoagulation in critically ill patients with COVID-19 associated AKI: A pilot study.
    Di Mario F; Regolisti G; Di Maria A; Parmigiani A; Benigno GD; Picetti E; Barbagallo M; Greco P; Maccari C; Fiaccadori E
    J Crit Care; 2021 Jun; 63():22-25. PubMed ID: 33611151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No.
    Jimenez D; Rali P; Doerschug K
    Chest; 2022 Jun; 161(6):1448-1451. PubMed ID: 35550714
    [No Abstract]   [Full Text] [Related]  

  • 24. POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes.
    Tritschler T; Le Gal G; Brosnahan S; Carrier M
    Chest; 2022 Jun; 161(6):1446-1448. PubMed ID: 35469670
    [No Abstract]   [Full Text] [Related]  

  • 25. In non-critically ill patients with COVID-19, therapeutic anticoagulation improved survival to discharge without organ support.
    Donato AA
    Ann Intern Med; 2021 Dec; 174(12):JC134. PubMed ID: 34871053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Need for Chemo-Thromboprophylaxis Protocols in Critically Ill COVID-19 Patients.
    Ehrlich H; McKenney M; Elkbuli A
    Am Surg; 2021 May; 87(5):698-699. PubMed ID: 33283541
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19: A retrospective cohort study.
    Eman A; Balaban O; Süner KÖ; Cırdı Y; Şahin F; Demir G; Pekşen Ö; Musmul A; Erdem AF
    Saudi Med J; 2022 Jul; 43(7):715-722. PubMed ID: 35830988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatal Disseminated Intravascular Coagulopathy in Covid-19: A Small Case Series.
    Kazmi S; Herekar F; Sarfaraz S
    Semin Thromb Hemost; 2021 Jun; 47(4):427-430. PubMed ID: 33336328
    [No Abstract]   [Full Text] [Related]  

  • 29. Monitoring of unfractionated heparin in critically ill patients.
    Aarab R; van Es J; de Pont AC; Vroom MB; Middeldorp S
    Neth J Med; 2013 Nov; 71(9):466-71. PubMed ID: 24218420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venous thromboembolism prophylaxis in critically ill patients.
    McLeod AG; Geerts W
    Crit Care Clin; 2011 Oct; 27(4):765-80, v. PubMed ID: 22082513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dalteparin in critically ill patients.
    Esterbrook G; Hart S
    N Engl J Med; 2011 Jul; 365(2):179; author reply 180. PubMed ID: 21751920
    [No Abstract]   [Full Text] [Related]  

  • 32. Time to recommend heparin and low-molecular-weight heparins in thromboprophylaxis in medical-surgical critically ill patients.
    Volpi N
    Crit Care Med; 2013 Sep; 41(9):2224-6. PubMed ID: 23979368
    [No Abstract]   [Full Text] [Related]  

  • 33. Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?
    de Montmollin E; Faille D; Andrieu V; Ajzenberg N; Timsit JF
    J Infect; 2021 May; 82(5):e20-e22. PubMed ID: 33549626
    [No Abstract]   [Full Text] [Related]  

  • 34. The Value of Thromboelastography (TEG) in COVID-19 Critical Illness as Illustrated by a Case Series.
    Wang J; Hajizadeh N; Shore-Lesserson L
    J Cardiothorac Vasc Anesth; 2022 Aug; 36(8 Pt A):2536-2543. PubMed ID: 34802831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin resistance in COVID-19 patients in the intensive care unit.
    White D; MacDonald S; Bull T; Hayman M; de Monteverde-Robb R; Sapsford D; Lavinio A; Varley J; Johnston A; Besser M; Thomas W
    J Thromb Thrombolysis; 2020 Aug; 50(2):287-291. PubMed ID: 32445064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dalteparin versus unfractionated heparin in critically ill patients.
    ; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
    N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dalteparin in critically ill patients.
    Smythe MA; Koerber JM
    N Engl J Med; 2011 Jul; 365(2):179-80; author reply 180. PubMed ID: 21751919
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-Xa activity by weight in critically ill patients receiving unfractionated heparin for venous thromboembolism prophylaxis.
    Aggarwal MV; Jarrell AS; Gilmore VT; Aboagye JK; Haut ER; Hobson DB; Lau BD; Kickler T; Kraus PS; Shaffer DL; Shermock KM; Streiff MB; Zheng G; Kruer RM
    J Crit Care; 2019 Aug; 52():180-185. PubMed ID: 31078999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological and Mechanical Thromboprophylaxis in Critically Ill Patients: a Network Meta-Analysis of 12 Trials.
    Park J; Lee JM; Lee JS; Cho YJ
    J Korean Med Sci; 2016 Nov; 31(11):1828-1837. PubMed ID: 27709864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin and SARS-CoV-2: Multiple Pathophysiological Links.
    Di Micco P; Imbalzano E; Russo V; Attena E; Mandaliti V; Orlando L; Lombardi M; Di Micco G; Camporese G; Annunziata S; Piccinocchi G; Pacelli W; Del Guercio M
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.